Business Wire

LILIUM-OTSUKA-CO.,-LTD.

2.10.2015 14:01:58 CEST | Business Wire | Pressemeddelelse

Del
Lilium Otsuka: Lilium® α-200, a Continuous Urine Volume Sensor, Will Be Launched in Japan

Lilium Otsuka Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd. will begin selling the Lilium® α-200, a continuous, non-invasive bladder urine volume sensor, on November 2, 2015.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151002005301/en/

This product makes it possible to continuously monitor urination schedules in patients who have lost the urge to urinate. It is anticipated that this will alleviate the need for daily, lifestyle-restricting indwelling bladder (“Foley”) catheters and the anxiety of incontinence.

Problems with urination independence and control are known to determine the ability of patients to return home from the hospital, and impose a heavy burden on nursing and caregiving services. Lilium α-200 is expected to greatly contribute to the improvement of patient quality of life, and to reduce labor and improve the efficacy of those engaged in nursing and caregiving. Further, Lilium Otsuka expects to make a significant contribution to holistic treatments which impact the dignity of patients.

“For patients with loss of urge or urinary difficulty, the beauty of this product lies in its ability to accurately monitor the size of the bladder (a measure of volume of urine retained in the bladder) and the ability to schedule bathroom trips or self-catheterization.” said Dr. Osamu Yokoyama M.D., Ph.D., president of the Japanese Continence Society and professor on the Faculty of Medical Sciences, the University of Fukui, “As the Japanese Continence Society initiates a certified physician system next year to begin training doctors who can professionally manage continence care, this device is thought to provide a good method to support discharge of patients to their homes.”

About Lilium Otsuka

Lilium Otsuka is a subsidiary company of Otsuka Holdings Co., Ltd. (TOKYO:4578) established in Kanagawa, Japan. It is dedicated to standardizing the practice of measuring urinary volume as a “fifth vital sign” through developing innovative bladder health products.

About Lilium ® α-200

Lilium® α-200 is an innovative, hand-held urine volume sensor which works with two AA batteries. The device measures not only bladder urine residual but also provides alerts on appropriate timing for clean-intermittent catheterization through continuous urine volume measurement.

Contact:

Keiko Yoshimura
Lilium Otsuka Co., Ltd.
+81-42-704-3822
lilium_info@otsuka.jp
Website link: http://lilium200.jp/index-en.html

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release

QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve

SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release

New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p

Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release

By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c

Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release

Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S

European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye